Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation

K. Iijima,K. Nozu,K. Kamei,M. Nakayama,S. Ito,K. Matsuoka,T. Ogata,H. Kaito,K. Nakanishi,M. Matsuo

DOI: https://doi.org/10.1007/s00467-010-1514-1

2010-04-13

Abstract:

What problem does this paper attempt to address?

Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study

Lucía Quintana-Castanedo,Silvia Sánchez-Ramón,Rocío Maseda,Nuria Illera,Isabel Pérez-Conde,Marta Molero-Luis,Nora Butta,Elena G Arias-Salgado,Elena Monzón-Manzano,Pilar Zuluaga,Lucía Martínez-Santamaría,Miguel Fernández-Arquero,Sara G Llames,Álvaro Meana,Raúl de Lucas,Marcela Del Río,Ángeles Vicente,María José Escámez,Rosa Sacedón

DOI: https://doi.org/10.1111/exd.15146

Abstract:Patients with recessive dystrophic epidermolysis bullosa (RDEB) experience numerous complications, which are exacerbated by inflammatory dysregulation and infection. Understanding the immunological mechanisms is crucial for selecting medications that balance inflammation control and immunocompetence. In this cross-sectional study, aiming to identify potential immunotherapeutic targets and inflammatory biomarkers, we delved into the interrelationship between clinical severity and systemic inflammatory parameters in a representative RDEB cohort. Encompassing 84 patients aged 1-67 and spanning all three Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) severity categories, we analysed the interrelationship of infection history, standard inflammatory markers, systemic cytokines and Ig levels to elucidate their roles in RDEB pathophysiology. Our findings identify C-reactive protein as an excellent biomarker for disease severity in RDEB. A type 2 inflammatory profile prevails among moderate and severe RDEB patients, correlating with dysregulated circulating IgA and IgG. These results underscore the IL4/IL13 pathways as potential evidence-based therapeutic targets. Moreover, the complete inflammatory scenario aligns with Staphylococcus aureus virulence mechanisms. Concurrently, abnormalities in IgG, IgE and IgM levels suggest an immunodeficiency state in a substantial number of the cohort's patients. Our results provide new insights into the interplay of infection and immunological factors in the pathogenesis of RDEB.
Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions

Cristian De Gregorio,Evelyng Catalán,Gabriel Garrido,Pilar Morandé,Jimena Castillo Bennett,Catalina Muñoz,Glenda Cofré,Ya-Lin Huang,Bárbara Cuadra,Paola Murgas,Margarita Calvo,Fernando Altermatt,María Joao Yubero,Francis Palisson,Andrew P South,Marcelo Ezquer,Ignacia Fuentes

DOI: https://doi.org/10.1186/s40659-023-00437-2

2023-05-10

Abstract:Background: Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare inherited skin disease caused by variants in the COL7A1 gene, coding for type VII collagen (C7), an important component of anchoring fibrils in the basement membrane of the epidermis. RDEB patients suffer from skin fragility starting with blister formation and evolving into chronic wounds, inflammation and skin fibrosis, with a high risk of developing aggressive skin carcinomas. Restricted therapeutic options are limited by the lack of in vitro models of defective wound healing in RDEB patients. Results: In order to explore a more efficient, non-invasive in vitro model for RDEB studies, we obtained patient fibroblasts derived from discarded dressings) and examined their phenotypic features compared with fibroblasts derived from non-injured skin of RDEB and healthy-donor skin biopsies. Our results demonstrate that fibroblasts derived from RDEB chronic wounds (RDEB-CW) displayed characteristics of senescent cells, increased myofibroblast differentiation, and augmented levels of TGF-β1 signaling components compared to fibroblasts derived from RDEB acute wounds and unaffected RDEB skin as well as skin from healthy-donors. Furthermore, RDEB-CW fibroblasts exhibited an increased pattern of inflammatory cytokine secretion (IL-1β and IL-6) when compared with RDEB and control fibroblasts. Interestingly, these aberrant patterns were found specifically in RDEB-CW fibroblasts independent of the culturing method, since fibroblasts obtained from dressing of acute wounds displayed a phenotype more similar to fibroblasts obtained from RDEB normal skin biopsies. Conclusions: Our results show that in vitro cultured RDEB-CW fibroblasts maintain distinctive cellular and molecular characteristics resembling the inflammatory and fibrotic microenvironment observed in RDEB patients' chronic wounds. This work describes a novel, non-invasive and painless strategy to obtain human fibroblasts chronically subjected to an inflammatory and fibrotic environment, supporting their use as an accessible model for in vitro studies of RDEB wound healing pathogenesis. As such, this approach is well suited to testing new therapeutic strategies under controlled laboratory conditions.
Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa

Elke Niebergall-Roth,Kathrin Dieter,Cristina Daniele,Silvia Fluhr,Maria Khokhrina,Ines Silva,Christoph Ganss,Markus H Frank,Mark A Kluth

DOI: https://doi.org/10.3390/cells12111468

IF: 6

2023-05-24

Cells

Abstract:Recessive dystrophic epidermolysis (RDEB) is a rare, inherited, and currently incurable skin blistering disorder characterized by cyclically recurring wounds coexisting with chronic non-healing wounds. In a recent clinical trial, three intravenous infusions of skin-derived ABCB5+ mesenchymal stromal cells (MSCs) to 14 patients with RDEB improved the healing of wounds that were present at baseline. Since in RDEB even minor mechanical forces perpetually provoke the development of new or recurrent wounds, a post-hoc analysis of patient photographs was performed to specifically assess the effects of ABCB5+ MSCs on new or recurrent wounds by evaluating 174 wounds that occurred after baseline. During 12 weeks of systemic treatment with ABCB5+ MSCs, the number of newly occurring wounds declined. When compared to the previously reported healing responses of the wounds present at baseline, the newly occurring wounds healed faster, and a greater portion of healed wounds remained stably closed. These data suggest a previously undescribed skin-stabilizing effect of treatment with ABCB5+ MSCs and support repeated dosing of ABCB5+ MSCs in RDEB to continuously slow the wound development and accelerate the healing of new or recurrent wounds before they become infected or progress to a chronic, difficult-to-heal stage.
Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis

E Chacón-Solano,C León,M Carretero,M García,R Sánchez-Domínguez,F Quero,E Méndez-Jiménez,J Bonafont,B Ruiz-Mezcua,M J Escámez,F Larcher,M Del Río

DOI: https://doi.org/10.1016/j.matbio.2022.06.007

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic extracellular matrix disease caused by deficiency in type VII collagen (Col VII). The disease manifests with devastating mucocutaneous fragility leading to progressive fibrosis and metastatic squamous cell carcinomas. Although Col VII abundance is considered the main predictor of symptom course, previous studies have revealed the existence of mutation-independent mechanisms that control disease progression. Here, to investigate and validate new molecular modifiers of wound healing and fibrosis in a natural human setting, and toward development of disease-modulating treatment of RDEB, we performed gene expression profiling of primary fibroblast from RDEB siblings with marked phenotypic variations, despite having equal COL7A1 genotype. Gene enrichment analysis suggested that severe RDEB was associated with enhanced response to TGF-β stimulus, oxidoreductase activity, and cell contraction. Consistently, we found an increased response to TGF-β, higher levels of basal and induced reactive oxygen species (ROS), and greater contractile ability in collagen lattices in RDEB fibroblasts (RDEBFs) from donors with severe RDEB vs mild RDEB. Treatment with antioxidants allowed a reduction of the pro-fibrotic and contractile phenotype. Importantly, our analyses revealed higher expression and deposition in skin of the relatively uncharacterized small leucine-rich extracellular proteoglycan PRELP/prolargin associated with milder RDEB manifestations. Mechanistic investigations showed that PRELP effectively attenuated fibroblasts' response to TGF-β1 stimulus and cell contractile capacity. Moreover, PRELP overexpression in RDEBFs enhanced RDEB keratinocyte attachment to fibroblast-derived extracellular matrix in the absence of Col VII. Our results highlight the clinical relevance of pro-oxidant status and hyper-responsiveness to TGF-β in RDEB severity and progression. Of note, our study also reveals PRELP as a novel and natural TGF-β antagonist with a likely dermo-epidermal pro-adhesive capacity.
The Kilauea Volcano Observatory.

W. Cross,W. Bowie,A. L. Day,H. E. Gregory,H. F. Reid

DOI: https://doi.org/10.1073/PNAS.6.12.706

1920-12-01

Abstract:
ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa

Kathrin Dieter,Elke Niebergall-Roth,Cristina Daniele,Silvia Fluhr,Natasha Y Frank,Christoph Ganss,Dimitra Kiritsi,John A McGrath,Jakub Tolar,Markus H Frank,Mark A Kluth

DOI: https://doi.org/10.1016/j.jcyt.2023.01.015

IF: 6.196

Cytotherapy

Abstract:Background and aims: Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary, rare, devastating and life-threatening skin fragility disorder with a high unmet medical need. In a recent international, single-arm clinical trial, treatment of 16 patients (aged 6-36 years) with three intravenous infusions of 2 × 106 immunomodulatory ABCB5+ dermal mesenchymal stromal cells (MSCs)/kg on days 0, 17 and 35 reduced disease activity, itch and pain. A post-hoc analysis was undertaken to assess the potential effects of treatment with ABCB5+ MSCs on the overall skin wound healing in patients suffering from RDEB. Methods: Documentary photographs of the affected body regions taken on days 0, 17, 35 and at 12 weeks were evaluated regarding proportion, temporal course and durability of wound closure as well as development of new wounds. Results: Of 168 baseline wounds in 14 patients, 109 (64.9%) wounds had closed at week 12, of which 63.3% (69 wounds) had closed already by day 35 or day 17. Conversely, 74.2% of the baseline wounds that had closed by day 17 or day 35 remained closed until week 12. First-closure ratio within 12 weeks was 75.6%. The median rate of newly developing wounds decreased significantly (P = 0.001) by 79.3%. Conclusions: Comparison of the findings with published data from placebo arms and vehicle-treated wounds in controlled clinical trials suggests potential capability of ABCB5+ MSCs to facilitate wound closure, prolongate wound recurrence and decelerate formation of new wounds in RDEB. Beyond suggesting therapeutic efficacy for ABCB5+ MSCs, the analysis might stimulate researchers who develop therapies for RDEB and other skin fragility disorders to not only assess closure of preselected target wounds but pay attention to the patients' dynamic and diverse overall wound presentation as well as to the durability of achieved wound closure and the development of new wounds. Trial registration: Clinicaltrials.gov NCT03529877; EudraCT 2018-001009-98.
Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

Lara Cutlar,Udo Greiser,Wenxin Wang

DOI: https://doi.org/10.1111/exd.12246

2014-01-01

Experimental Dermatology

Abstract:The replacement of a defective gene with a fully functional copy is the goal of the most basic gene therapy. Recessive dystrophic epidermolysis bullosa (RDEB) is characterised by a lack of adhesion of the epidermis to the dermis. It is an ideal target for gene therapy as all variants of hereditary RDEB are caused by mutations in a single gene, COL7A1, coding for type VII collagen, a key component of anchoring fibrils that secure attachment of the epidermis to the dermis. RDEB is one of the most severe variants in the epidermolysis bullosa (EB) group of heritable skin diseases. Epidermolysis bullosa is defined by chronic fragility and blistering of the skin and mucous membranes due to mutations in the genes responsible for production of the basement membrane proteins. This condition has a high personal, medical and socio-economic impact. People with RDEB require a broad spectrum of medications and specialised care. Due to this being a systemic condition, most research focus is in the area of gene therapy. Recently, preclinical works have begun to show promise. They focus on the virally mediated ex vivo correction of autologous epithelium. These corrected cells are then to be expanded and grafted onto the patient following the lead of the first successful gene therapy in dermatology being a grafting of corrected tissue for junctional EB treatment. Current progress, outstanding challenges and future directions in translating these approaches in clinics are reviewed in this article.
Targeted lipidomics: signaling lipids and drugs of abuse.

R. Rapaka,D. Piomelli,S. Spiegel,N. Bazan,E. Dennis

DOI: https://doi.org/10.1016/J.PROSTAGLANDINS.2005.06.005

IF: 3.813

2005-09-01

Prostaglandins & Other Lipid Mediators

Abstract:
Trust Based Secure In-network Data Processing Schema in Wireless Sensor Networks

Hailin Feng,Guanghui Li,W. Lu,Leijun Huang

DOI: https://doi.org/10.4304/jnw.6.2.295-302

2011-01-02

Abstract:In wireless sensor networks, i n-network data processing plays an important role to reduce the transmitting energy and data redundancy in large-scale sensor networks. However, the security of wireless sensor networks is a challenging problem with the compromised sensor nodes in the networks. This paper introduced a trusted secure in-network data processing schema to enhance the data security of wireless sensor networks. T he secure in-network processing tree is constructed firstly , then a judgment method based on trust schema was used to detect whether a sensor node has potential misbehavior. A detecting algorithm is used to searching abnormal data from the reporting reading of sensor nodes. After the detection, a new local recovery schema is proposed to reduce the possibility to become isolated nodes, which will increase the security level in data aggregation in wireless sensor networks. The performance analysis shows the efficiency of the schema.
Elevated expression of interleukin‐6 (IL‐6) and serum amyloid A (SAA) in the skin and the serum of recessive dystrophic epidermolysis bullosa: Skin as a possible source of IL‐6 through Toll‐like receptor ligands and SAA

Yoshio Kawakami,Ai Kajita,Ken‐Ichi Hasui,Yoshihiro Matsuda,Keiji Iwatsuki,Shin Morizane

DOI: https://doi.org/10.1111/exd.15040

2024-03-02

Experimental Dermatology

Abstract:The effect of persistent skin inflammation on extracutaneous organs and blood is not well studied. Patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of the inherited blistering skin disorder, have widespread and persistent skin ulcers, and they develop various complications including anaemia, hyperglobulinaemia, hypoalbuminaemia and secondary amyloidosis. These complications are associated with the bioactivities of IL‐6, and the development of secondary amyloidosis requires the persistent elevation of serum amyloid A (SAA) level. We found that patients with RDEB had significantly higher serum levels of IL‐6 and SAA compared to healthy volunteers and patients with psoriasis or atopic dermatitis. Both IL‐6 and SAA were highly expressed in epidermal keratinocytes and dermal fibroblasts of the skin ulcer lesions. Keratinocytes and fibroblasts surrounding the ulcer lesions are continuously exposed to Toll‐like receptor (TLR) ligands, pathogen‐associated and damage‐associated molecular pattern molecules. In vitro, TLR ligands induced IL‐6 expression via NF‐κB in normal human epidermal keratinocytes (NHEKs) and dermal fibroblasts (NHDFs). SAA further induced the expression of IL‐6 via TLR1/2 and NF‐κB in NHEKs and NHDFs. The limitation of this study is that NHEKs and NHDFs were not derived from RDEB patients. These observations suggest that TLR‐mediated persistent skin inflammation might increase the risk of IL‐6‐related systemic complications, including RDEB.

dermatology
Reactive oxygen species mediated DNA damage is essential for abnormal erythropoiesis in peroxiredoxin II(-/-) mice.

Taeho Kwon,Ying-Hao Han,S. Hong,D. Lee,H. Ha,S. Kang,Wei Li,D. Yoon,Dae-Yeul Yu

DOI: https://doi.org/10.1016/j.bbrc.2012.06.113

2012-07-20

Abstract:
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial

Irina Gurevich,Pooja Agarwal,PeiPei Zhang,John A. Dolorito,Stacie Oliver,Henry Liu,Nicholas Reitze,Nikhil Sarma,Isin Sinem Bagci,Kunju Sridhar,Visesha Kakarla,Vamsi K. Yenamandra,Mark O’Malley,Marco Prisco,Sara F. Tufa,Douglas R. Keene,Andrew P. South,Suma M. Krishnan,M. Peter Marinkovich

DOI: https://doi.org/10.1038/s41591-022-01737-y

IF: 82.9

2022-03-28

Nature Medicine

Abstract:Abstract Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1 , the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDEB mice and human RDEB xenografts. Subsequently, a randomized, placebo-controlled, phase 1 and 2 clinical trial (NCT03536143) evaluated matched wounds from nine RDEB patients receiving topical B-VEC or placebo repeatedly over 12 weeks. No grade 2 or above B-VEC-related adverse events or vector shedding or tissue-bound skin immunoreactants were noted. HSV-1 and C7 antibodies sometimes presented at baseline or increased after B-VEC treatment without an apparent impact on safety or efficacy. Primary and secondary objectives of C7 expression, anchoring fibril assembly, wound surface area reduction, duration of wound closure, and time to wound closure following B-VEC treatment were met. A patient-reported pain–severity secondary outcome was not assessed given the small proportion of wounds treated. A global assessment secondary endpoint was not pursued due to redundancy with regard to other endpoints. These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma

Catherine A.A. Lee,Siyuan Wu,Yuen Ting Chow,Eric Kofman,Valencia Williams,Megan Riddle,Cindy Eide,Christen L. Ebens,Markus H. Frank,Jakub Tolar,Kristen P. Hook,Saud H. AlDubayan,Natasha Y. Frank

DOI: https://doi.org/10.1016/j.jid.2023.11.025

IF: 7.59

2024-01-27

Journal of Investigative Dermatology

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a severely debilitating disorder caused by mutations in COL7A1 and is characterized by extreme skin fragility, chronic inflammation and fibrosis. A majority of RDEB patients develop squamous cell carcinoma (SCC), a highly aggressive skin cancer with limited treatment options currently available. In this study, we utilized an approach leveraging WGS and RNA-seq across three different tissues in a single RDEB patient to gain insight into...

dermatology
Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa

Courtney Popp,William Miller,Cindy Eide,Jakub Tolar,John A. McGrath,Christen L. Ebens

DOI: https://doi.org/10.1016/j.jid.2024.03.008

IF: 7.59

2024-04-15

Journal of Investigative Dermatology

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disease resulting from inadequate type VII collagen (C7). Although recurrent skin blisters and wounds are the most apparent disease features, the impact of C7 loss is not confined to the skin and mucous membranes. RDEB is a systemic disease marred by chronic inflammation, fibrotic changes, pain, itch, and anemia, significantly impacting QOL and survival. In this narrative review, we summarize these systemic features of RDEB and...

dermatology
New options to manage epidermolysis bullosa

Laura Bolton

DOI: https://doi.org/10.25270/wnds/22-297299

Abstract:RDEB is a genetic skin disorder involving COL7A1, the gene encoding C7, which is a component of the fibers anchoring the epidermis to the dermis. Affected patients (about 1.35 per million persons in the United States) experience lifelong painful itching, blistering, fibrosis, impaired healing, and scarring, with increased likelihood of infection and cancer. RCT involving those affected by RDEB are rare with limited sample sizes due to the low prevalence of this genetic disorder. Treatment with topical or systemic agents has not consistently improved patient outcomes. Therapies focused on replacing C7 using autologous bone marrow or keratinocyte grafts have been difficult, with high complication rates, and have been met with mixed success. Recent HSV-1 vector research4 led to development of HSV-1 vectors capable of transferring the COL7A1 coding sequence to keratinocytes and fibroblasts in vitro and to mice deficient in C7, as well as to RDEB human skin xenografts. This research offered new opportunities for gene therapy for patients with RDEB. In this final Evidence Corner, readers are invited to consider the implications of 2 small RCTs that suggest fruitful avenues for RDEB research and practice. The first study describes a pioneering phase 1 and 2 RCT of topical gene therapy for RDEB. The second study describes a small crossover RCT exploring the effect of topical calcipotriol (VD3) ointment on wound healing and pruritis in patients with RDEB.
Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa

Irene Jover,Maria C. Ramos,María José Escámez,Estrella Lozoya,José R. Tormo,Diana de Prado-Verdún,Ángeles Mencía,Mercè Pont,Carles Puig,Marie-Helene Larraufie,Cristina Gutiérrez-Caballero,Fernando Reyes,Juan Luis Trincado,Vicente García-González,Rosario Cerrato,Miriam Andrés,Maribel Crespo,Francisca Vicente,Nuria Godessart,Olga Genilloud,Fernando Larcher,Arsenio Nueda

DOI: https://doi.org/10.1038/s41598-024-67398-8

IF: 4.6

2024-08-19

Scientific Reports

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disease caused by loss of function mutations in the gene coding for collagen VII (C7) due to deficient or absent C7 expression. This disrupts structural and functional skin architecture, leading to blistering, chronic wounds, inflammation, important systemic symptoms affecting the mouth, gastrointestinal tract, cornea, and kidney function, and an increased skin cancer risk. RDEB patients have an extremely poor quality of life and often die at an early age. A frequent class of mutations in RDEB is premature termination codons (PTC), which appear in homozygosity or compound heterozygosity with other mutations. RDEB has no cure and current therapies are mostly palliative. Using patient-derived keratinocytes and a library of 8273 small molecules and 20,160 microbial extracts evaluated in a phenotypic screening interrogating C7 levels, we identified three active chemical series. Two of these series had PTC readthrough activity, and one upregulated C7 mRNA, showing synergistic activity when combined with the reference readthrough molecule gentamicin. These compounds represent novel potential small molecule-based systemic strategies that could complement topical-based treatments for RDEB.

multidisciplinary sciences
Gamma-secretase inhibitors down-regulate the pro-fibrotic Notch signaling pathway in recessive dystrophic epidermolysis bullosa

Angelo Giuseppe Condorelli,Rebecca Nobili,Anita Muglia,Giorgia Scarpelli,Elisa Marzuolo,Cristiano De Stefanis,Rossella Rota,Andrea Diociaiuti,Rita Alaggio,Daniele Castiglia,Teresa Odorisio,May El Hachem,Giovanna Zambruno

DOI: https://doi.org/10.1016/j.jid.2023.10.045

IF: 7.59

2024-01-01

Journal of Investigative Dermatology

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare skin fragility disorder caused by mutations in COL7A1. RDEB is hallmarked by trauma-induced unremitting blistering, chronic wounds with inflammation, and progressive fibrosis, leading to severe disease complications. There is currently no cure for RDEB-associated fibrosis. Our previous studies and increasing evidence highlighted the profibrotic role of NOTCH pathway in different skin disorders, including RDEB. In this study, we further investigated the role of NOTCH signaling in RDEB pathogenesis and explored the effects of its inhibition by γ-secretase inhibitors DAPT and PF-03084014 (nirogacestat). Our analyses demonstrated that JAG1 and cleaved NOTCH1 are upregulated in primary RDEB fibroblasts (ie, RDEB-derived fibroblasts) compared with controls, and their protein levels are further increased by TGF-β1 stimulation. Functional assays unveiled the involvement of JAG1/NOTCH1 axis in RDEB fibrosis and demonstrated that its blockade counteracts a variety of fibrotic traits. In particular, RDEB-derived fibroblasts treated with PF-03084014 showed (i) a significant reduction of contractility, (ii) a diminished secretion of TGF-β1 and collagens, and (iii) the downregulation of several fibrotic proteins. Although less marked than PF-03084014-treated cells, RDEB-derived fibroblasts exhibited a reduction of fibrotic traits also upon DAPT treatment. This study provides potential therapeutic strategies to antagonize RDEB fibrosis onset and progression.

dermatology
Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells

Akinori Matsuda,Toshio Hasegawa,Yuri Ikeda,Akino Wada,Shigaku Ikeda

DOI: https://doi.org/10.1016/j.jdermsci.2024.05.004

Abstract:Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin fragility disorder caused by mutations in the COL7A1 gene, which encodes type VII collagen (COL7), the main constituent of anchoring fibrils for attaching the epidermis to the dermis. Persistent skin erosions frequently result in intractable ulcers in RDEB patients. Adipose-derived mesenchymal stromal cells (AD-MSCs) are easily harvested in large quantities and have low immunogenicity. Therefore, they are suitable for clinical use, including applications involving allogeneic cell transplantation. Keratinocyte-like cells transdifferentiated from AD-MSCs (KC-AD-MSCs) express more COL7 than undifferentiated AD-MSCs and facilitate skin wound healing with less contracture. Therefore, these cells can be used for skin ulcer treatment in RDEB patients. Objective: We investigated whether KC-AD-MSCs transplantation ameliorated the RDEB phenotype severity in the grafted skin of a RDEB mouse model (col7a1-null) on the back of the immunodeficient mouse. Methods: KC-AD-MSCs were intradermally injected into the region surrounding the skin grafts, and this procedure was repeated after 7 days. After a further 7-day interval, the skin grafts were harvested. Results: Neodeposition of COL7 and generation of anchoring fibrils at the dermal-epidermal junction were observed, although experiments were based on qualitative. Conclusion: KC-AD-MSCs may correct the COL7 insufficiency, repair defective/reduced anchoring fibrils, and improve skin integrity in RDEB patients.
CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

Xianqing Wang,Xi Wang,Yinghao Li,A. Sigen,Bei Qiu,Albina Bushmalyova,Zhonglei He,Wenxin Wang,Irene Lara-Saez

DOI: https://doi.org/10.1016/j.omtm.2023.101134

IF: 5.849

2023-01-01

Molecular Therapy — Methods & Clinical Development

Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is an autosomal monogenic skin disease caused by mutations in COL7A1 gene and lack of functional type VII collagen (C7). Currently, there is no cure for RDEB, and most of the gene therapies under development have been designed as ex vivo strategies because of the shortage of efficient and safe carriers for gene delivery. Herein, we designed, synthesized, and screened a new group of highly branched poly(β amino ester)s (HPAEs) as non-viral carriers for the delivery of plasmids encoding dual single-guide RNA (sgRNA)-guided CRISPR-Cas9 machinery to delete COL7A1 exon 80 containing the c.6527dupC mutation. The selected HPAEs (named PTTA-DATOD) showed robust transfection efficiency, comparable with or surpassing that of leading commercial gene transfection reagents such as Lipofectamine 3000, Xfect, and jetPEI, while maintaining negligible cytotoxicity. Furthermore, CRISPR-Cas9 plasmids delivered by PTTA-DATOD achieved efficient targeted deletion and restored bulk C7 production in RDEB patient keratinocyte polyclones. The non-viral CRISPR-Cas9-based COL7A1 exon deletion approach developed here has great potential to be used as a topical treatment for RDEB patients with mutations in COL7A1 exon 80. Besides, this therapeutic strategy can easily be adapted for mutations in other COL7A1 exons, other epidermolysis bullosa subtypes, and other genetic diseases.
Crosstalk mechanism between injured epithelia and bone marrow

Katsuto Tamai,Yasushi Kikuchi,Shin Iinuma,Ryo Fujita,Nao Manjyo,Yasufumi Kaneda

DOI: https://doi.org/10.1096/fasebj.26.1_supplement.335.2

2012-04-01

The FASEB Journal

Abstract:In the epidermis, resident stem/progenitor cells are involved in the complete renewal of the stratified squamous epithelium every 2–4 weeks and thus contribute to tissue homeostasis. In patients with the inherited chronic blistering skin disorder, recessive dystrophic epidermolysis bullosa (RDEB), however, the epidermal stem cell pool is continually depleted as a result of detachment of full‐thickness epidermis due to lack of the basement membrane protein, type VII collagen (Col 7). Nevertheless, the epidermis in RDEB continues to be renewed, suggesting there may be a mechanism to supplement epithelial stem/progenitor cells from extracutaneous sources. Here, we demonstrate that the detached epithelium from a Col 7‐null mouse model of RDEB will release abundant high mobility group box 1 (HMGB1), which mobilizes PDGFRα‐positive msenchymal stem cells from bone marrow into the circulation to repair the blistered skin. We believe that this study has broader implications for clinical medicine in identifying a means of mobilizing and recruiting particular bone marrow cells germane to tissue repair.

Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation

Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study

Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions

Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa

Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis

The Kilauea Volcano Observatory.

ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa

Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

Targeted lipidomics: signaling lipids and drugs of abuse.

Trust Based Secure In-network Data Processing Schema in Wireless Sensor Networks

Elevated expression of interleukin‐6 (IL‐6) and serum amyloid A (SAA) in the skin and the serum of recessive dystrophic epidermolysis bullosa: Skin as a possible source of IL‐6 through Toll‐like receptor ligands and SAA

Reactive oxygen species mediated DNA damage is essential for abnormal erythropoiesis in peroxiredoxin II(-/-) mice.

In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial

Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma

Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa

New options to manage epidermolysis bullosa

Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa

Gamma-secretase inhibitors down-regulate the pro-fibrotic Notch signaling pathway in recessive dystrophic epidermolysis bullosa

Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

Crosstalk mechanism between injured epithelia and bone marrow